LYT-100 in Post-acute COVID-19 Respiratory Disease

Study Name:
LYT-100 in Post-acute COVID-19 Respiratory Disease

Targeted Disease(s):
COVID-19

Purpose of Study:

To evaluate the safety and efficacy of LYT-100 with post-acute COVID-19 respiratory complications who were treated with, but no longer require mechanical ventilation, extracorporeal membrane oxygenation, non-invasive ventilation (eg CPAP or BiPAP), high-flow nasal oxygen therapy, or combination thereof.
 

Study Dates:
December 11, 2020 - December 30, 2021

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Lead Institution:
USC

Funding Source:
Puretech

ClinicalTrails.gov Identifier:
NCT04652518

Register for Trial
LUNG FORCE Expo
, | Jun 24, 2021